News

  • Jul 24, 2011

    Neurim Pharmaceuticals reports the results of stabilometric study of Circadin® demonstrating maintenance of postural stability (Read more)

  • Jun 22, 2011

    Neurim Pharmaceuticals is currently performing a clinical trial in Korea to obtain Circadin® marketing authorization

  • Jun 16, 2011

    Circadin® receives marketing authorization in New Zealand

  • May 17, 2011

    Circadin® use approved for up to 3 months in Switzerland

  • Apr 4, 2011

    Circadin® use approved for up to 3 months in Hong Kong

  • Jan 4, 2011

    TGA approves Circadin® use for up to 3 months

  • Oct 4, 2010

    Circadin® use approved for up to 3 months in Macedonia

  • Sep 6, 2010

    Circadin® use approved for up to 3 months in Croatia

  • Jul 5, 2010

    Circadin® approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months (Read more)

  • Apr 22, 2010

    EMEA approves Circadin® use for up to 3 months

  • Jun 11, 2009

    Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin® for Insomnia in Elderly Patients (Read more)

  • Sep 24, 2007

    Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

  • Jul 6, 2007

    Nycomed to market Circadin® for primary insomnia (Read more)

  • Jun 29, 2007

    An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®

  • Apr 27, 2007

    Neurim Pharmaceuticals announce that Circadin® for Primary Insomnia is recommended for approval in the EU (Read more)

  • Apr 26, 2007

    Summary of positive opinion for Circadin® (EMEA Press Release) (Read more)

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto (PedPRM) is now available in Norway!
    • Neurim Pharmaceuticals attends the ESCAP Congress in Vienna, Austria, 30 June – 2 July 2019
    • Slenyto (PedPRM) is now also available in Italy!
  • Partners

    Partners